PCN8: COST OF MANAGING SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES  by Annemans, LJ & Moeremans, K
434 Abstracts
one participating centre. Costs were evaluated for the
first hospitalization period post-transplant (FP) and for
the total duration of the follow-up period (OP). All prices
are expressed in FRF 2000 currency. Due to the small
sample size non-parametric rank testing was used to de-
termine whether significant differences existed (p  .05,
two sided).
RESULTS: Average FP cost per patient was 245,603.4
FRF (SD: 92,950.1) for C and 218,131.8 FRF for FI (SD:
61,711.7). Cost difference was 27,352.9 FRF (11%) in fa-
vor of the filgrastim arm (p  .15). Average OP cost per
patient was 267,784.9 FRF for C and 244,974.6 FRF for
FI. The cost difference did not change during follow-up.
Main cost drivers were, as expected, the cost of hospital-
ization and of IV antibiotic drugs. On average, FI patients
leave the ICU 2.8 days earlier than P patients during FP.
CONCLUSION: Use of filgrastim 24 hours post-PBPC
following high dose chemotherapy for n-HFL patients
could result in important cost reductions, mainly attrib-
utable to a shorter hospitalization in ICU and a lower use
of IV-antibiotics.
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OBJECTIVES: Hyperuricemia (HU) and tumour lysis
syndrome (TLS) are important complications leading to
increased morbidity and mortality in patients with acute
lymphoid or myeloid leukaemia (ALL/AML) and non-
Hodgkin lymphoma (NHL). The objective was to calcu-
late incidence and average cost of managing HU and TLS
in current daily practice from the payer’s perspective.
METHODS: Seven hundred eighty eight patients, both
adults and children, from Belgium, Holland, Spain and
the UK, who received induction treatment between 1999
and 2000, were screened retrospectively for the occur-
rence of HU or TLS. In patients fulfilling predefined diag-
nostic criteria, HU or TLS-related resource use was re-
corded and costs calculated by applying local unit costs.
RESULTS: HU was detected in 18.9% of screened pa-
tients, TLS in 5.0% despite 79% prophylaxis. The aver-
age cost of HU in the absence of TLS was 672 Euro (SE 
181), of which 218 Euro were for medication and 376
Euro for the hospital stay. The average cost of TLS was
7,342 Euro (SE  1,412) of which 5,837 Euro was re-
lated to additional hospitalization, 719 to interventions
(mainly dialysis) and 446 Euro to medication. TLS pa-
tients requiring dialysis incurred an average cost of
17,706 Euro compared to 3,887 in non-dialysed TLS
cases. Inter-country differences in costs were observed
and were solely due to differences in unit costs. Age or
underlying malignancy had no significant impact on
management costs.
CONCLUSIONS: Rates of HU and TLS observed were
at the low end of the range compared to previously pub-
lished reports in specific indications. There is a large vari-
ation in costs, and distributions are highly skewed. Pa-
tients developing TLS incur 11 times greater costs than
patients with HU in whom development of TLS can be
prevented. The main cost driver in TLS patients is the
need for interventions (dialysis and haemofiltration) that
require ICU admission and extra hospital stay.
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OBJECTIVE: In the United Kingdom NHS, approxi-
mately 200,000 central venous catheters are inserted in
adult patients per year. The most frequently inserted cen-
tral venous catheter is the Hickman line. As the mean
cost of a Hickman line insertion is estimated to be £450,
the annual cost to the NHS is substantial.
METHODS: A prospective randomised controlled trial
was conducted at the Christie NHS Trust (UK) to com-
pare blind versus image-guided approaches to Hickman
line insertions. Blind insertions were performed at the pa-
tient’s bedside whilst image-guided insertions were per-
formed in the interventional x-ray suite. An incremental
cost-effectiveness analysis was carried out alongside the
clinical trial from the perspective of the NHS. Main clini-
cal outcome measures included pneumothorax, arterial
puncture and catheter tip misplacement. The primary
economic outcome of interest was the incremental cost
per misplaced catheter tip avoided.
RESULTS: There were no clinically or statistically signif-
icant differences in pneumothorax or arterial puncture
rates across the blind arm (n  235) and the image-
guided arm (n  235) of the trial. Catheter tip misplace-
ment occurred in 1% of image-guided insertions and in
14% of blind insertions. However, patient and profes-
sional perception of catheter tip misplacement appeared
to demonstrate that the difference was statistically signif-
icant rather than clinically significant. Economic evalua-
tion results concluded that the total cost of image-guided
insertion of Hickman lines (£110,000) was similar to that
of blind Hickman-line insertions (£104,000).
CONCLUSIONS: The study shows that the vast majority
of Hickman-line insertions can be successfully inserted
blind at the bedside by nurses. Nevertheless, image-
guided insertions may lead to greater clinical benefits for
some groups of patients. Economic evaluation results
demonstrate that image-guided insertions are more cost-
effective than blind insertions. However, cost-effective-
ness of the image-guided approach is limited by the avail-
ability of the interventional x-ray suite.
